CNAT News and Press, Conatus Pharmaceuticals From 03/11/20

Conatus Pharmaceuticals (NASDAQ: CNAT ): Q4 GAAP EPS of -$0.08. More news on: Conatus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, March 11, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process. Recent Developments In January 2020, Conatus announ...

Do These Make The Cut Of Penny Stocks To Buy Right Now? Penny stocks usually trade below $5, but there are other penny stocks that might be trading at even lower levels. It is possible for investors to find value from among those stocks as well but you need a good eye for quality penny stoc...

SAN DIEGO , Feb. 6, 2020 /PRNewswire/ -- Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at the BIO CEO & Investor Conference takin...

Source (Shutterstock/Liya Graphics) Introduction Gilead Sciences ( GILD ) was positioned to be the poster child of Trump's plan to eradicate HIV, as outlined in my previous article . Like almost all outbreaks including the Wuhan coronavirus, the only effective way to complete...

SAN DIEGO , Jan. 30, 2020 /PRNewswire/ -- Histogen Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced it has expanded its partnership with leading global biopharmaceutical company, Allergan. The compan...

Penny Stocks To Watch After News If there’s one thing that can trigger a rally in penny stocks , it’s news. Whether it comes from a major industry leader or the company itself, penny stock news can become a big factor in breakouts or break downs. In fact, many times you’...

Conatus Pharmaceuticals (NASDAQ: CNAT ) and privately held Histogen have agreed to merge in an all-stock transaction. Conatus shareholders will own ~26% of the combined company while Histogen investors will own ~74%. More news on: Conatus Pharmaceuticals Inc., Healthcare stocks news, Sto...

Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and Combined Company Capitalization Expected to Support Operations into 2021 Companies to Hold a Joint Conference Call at 4:30 p.m. ET on January 28, 2020 SAN DIEGO, Jan. 28, 2020 (...

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member. “We are pleased to expand the perspective of our Board of Directors ...